A Study to Evaluate the Efficacy and Safety of ICP-248 in Subjects With Relapsed or Refractory Mantle Cell Lymphoma (APEX-06)
Clinical trial NCT07082686 · RECRUITING
Trial details
- NCT number
- NCT07082686
- Sponsor
- Beijing InnoCare Pharma Tech Co., Ltd.
- Status
- RECRUITING
- Phase
- Phase 2
- Study type
- INTERVENTIONAL
- Start date
- 2025-08-21
- Primary completion
- 2027-12-01
- Enrollment
- 75
Track trials programmatically
Sponsors, conditions and status changes through the Atlas API.